A PHASE 2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ZN-C3 IN SUBJECTS WITH HIGH-GRADE SEROUS OVARIAN, FAOLLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (ZN-c3-005/GOG-3066/DENALI)
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Azenosertib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms DENALI
- Sponsors K-Group Beta
- 25 Jun 2024 Planned number of patients changed from 100 to 102.
- 25 Jun 2024 Status changed from suspended to active, no longer recruiting.
- 19 Jun 2024 Planned number of patients changed from 90 to 100.